PAP
IKT icon

Persistent Asset Partners’s Inhibikase Therapeutics IKT Stock Holding History

Persistent Asset Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-93,430
Closed -$192K – 394
2025
Q4 		$192K Buy
+93,430
New +$149K 0.09% 216

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Persistent Asset Partners's IKT Position: Q1 2026 in Review

Persistent Asset Partners sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 93,430 shares — an estimated $192K sold.

Persistent Asset Partners first reported a position in IKT in Q4 2025 and held it in 1 quarter. The position peaked at $192K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Persistent Asset Partners reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 93,430 Inhibikase Therapeutics shares in Q1 2026, an estimated $192K.
  • Persistent Asset Partners first reported a position in Inhibikase Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Inhibikase Therapeutics position peaked at $192K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.